Please ensure Javascript is enabled for purposes of website accessibility

The Most Surprising FDA Decisions of 2013

By Max Macaluso - Apr 9, 2013 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We're only three months into 2013, but has the Food & Drug Administration already made some surprising decisions?

The Food and Drug Administration ensures that the benefits of newly approved drugs outweigh their potential side-effects. However, it's not always easy to predict which way the FDA will decide, and sometimes its decisions are very hard to interpret.

In the following video, health care analyst Max Macaluso discusses why two recent FDA decisions regarding diabetes medications developed by Novo Nordisk (NVO 0.35%) and Johnson & Johnson (JNJ 0.03%) surprised him this year, and how these decisions can impact investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.68 (0.03%) $0.06
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
NVO
$105.61 (0.35%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.